Navigation Links
Scientists find potential benefit of hypericin for recurrent brain tumors
Date:4/11/2011

SALT LAKE CITY Researchers have found that a synthetic version of hypericin, a compound naturally found in St. John's wort, may be a promising treatment for patients with recurrent malignant brain tumors. Their findings were published online on March 31, 2011 in the journal Cancer.

Malignant gliomas, tumors that arise in the brain or spine, are largely incurable cancers with a poor prognosis. An estimated 10,000 Americans are diagnosed each year with malignant gliomas, and their average one-year survival is approximately 50 percent. Laboratory studies have shown that synthetic hypericin strongly inhibits the growth of gliomas, due in part to its inhibitory effect on protein kinase C, a family of enzymes that promotes tumor proliferation.

"Because hypericin has shown dramatic results in stopping tumor growth in gliomas in the laboratory, we wanted to examine the safety and potential antitumor activity of synthetic hypericin in patients with recurrent malignant gliomas," says William T. Couldwell, MD, PhD, professor and chairman of neurosurgery at the University of Utah School of Medicine, and lead author on the study.

In this study, Couldwell and a team of scientists from across the US and Canada administered oral synthetic hypericin to patients with two types of gliomas, anaplastic astrocytoma and glioblastoma, whose tumors had recurred or progressed despite standard treatment. In order to evaluate the safety and tolerability of the drug, the researchers gave the patients gradually increasing dosages of synthetic hypericin and monitored them for adverse effects. Forty percent of the study participants were able to complete a three-month treatment regimen, demonstrating that hypericin is well-tolerated as an oral medication in this patient group.

Couldwell and his colleagues also examined response to treatment among this group of glioma patients. They found that 22 percent of all study participants achieved either stable disease or a partial response during treatment with hypericin. Of the 18 patients who completed at least 60 days of hypericin treatment, 50 percent achieved either stable disease or a partial response.

"The patients enrolled in our study were all individuals whose tumors had recurred or progressed after extensive prior therapy," says Couldwell.

"Finding evidence of potential antitumor activity among this very ill population of patients who had failed conventional treatment is a promising sign that hypericin could be useful as an adjunct to the current standard of care."

Gliomas are typically treated with a combination of surgery, radiation therapy, and chemotherapy. The investigators suggest that the future of hypericin in the treatment of malignant gliomas will most likely focus on the use of the synthetic compound either in conjunction with radiation therapy or other chemotherapeutic agents or in patients with resistant tumors.

"Despite advances in care, the prognosis for patients with malignant glioma remains poor. The next step is to examine the effect of hypericin if given earlier in the course of therapy," says Couldwell. "Since different chemotherapy agents have different mechanisms of action, it would be interesting to see if adding hypericin to existing treatment regimens for malignant glioma would have an additive or synergistic effect."


'/>"/>

Contact: Chris Nelson
christopher.nelson@hsc.utah.edu
801-581-7387
University of Utah Health Sciences
Source:Eurekalert

Related medicine news :

1. Scientists Pinpoint Area of Brain That Fears Losing Money
2. Scientists Discover How HIV Is Transmitted Between Men
3. Prevention Is Key Research Goal for Premature Babies, Scientists Say
4. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
5. Scientists find donut-shaped structure of enzyme involved in energy metabolism
6. Neuroscientists reveal new links that regulate brain electrical activity
7. Two UCSF Scientists to Receive Prestigious Dementia Research Honor
8. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
9. Scientists Spot Genetic Fingerprints of Individual Cancers
10. Scientists Unravel Mysteries of Intelligence
11. MSU scientists develop more effective method of predicting lead-poisoning risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
Breaking Medicine Technology: